Delani Diekmeier Speaks About Her Cancer Diagnosis and Treatment

Fifteen-year-old Delani Diekmeier is speaking publicly for the first time about her cancer diagnosis and ongoing treatment, Heute reported.

Key Clinical Takeaways:

• Delani Diekmeier, daughter of former professional soccer player Dennis Diekmeier, was diagnosed with an adrenal gland tumor in early 2025.
• Subsequent medical imaging identified metastases in both lungs, prompting a series of complex therapeutic decisions for the family.
• Despite recent treatment setbacks involving low efficacy rates, the teenager is organizing a charity event for the homeless in Hamburg in December.

Medical treatment for the teenager began in early 2025 when doctors surgically removed a tumor from her adrenal gland. Shortly after the initial operation, diagnostic scans revealed metastases in both lungs. Her mother, Dana Diekmeier, said that these pulmonary lesions continued to grow by July. A newly tested medication intended to target tissue from a lung metastasis showed efficacy in only one-third of laboratory tests.

Faced with limited success probabilities and potential severe side effects, the family decided against proceeding with that specific drug regimen. Delani Diekmeier shared her perspective on managing the diagnosis with Bild. “Man muss sich nicht einschließen. Es wird nichts besser, wenn du nur auf dem Sofa liegst und weinst. Es ändert nichts an der Tatsache,” she told Bild.

Public updates regarding the illness were previously provided by her parents. Her father, Dennis Diekmeier, first discussed the family situation publicly in September 2025 during an appearance on SPORT1, followed by a joint television interview on the Sky program Meine Geschichte. Shifting focus toward community engagement, the 15-year-old initiated plans to work as a waitress during a charity event for homeless individuals in Hamburg scheduled for December.

“Sie will anderen helfen. Ich bin sehr stolz auf sie,” Dana Diekmeier told Bild regarding her daughter’s upcoming volunteer work.

The family has not announced any alternative pharmacological interventions following the discontinuation of the recent drug trial. Doctors will continue clinical evaluations and monitoring of the lung metastases through the remainder of the year.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.